At Rejuvenation we rejuvenate cells by years in hours
At Rejuvenation we rejuvenate cells by years in hours
of telomere shortening reversed in 1 day
patents granted
in grant funding awarded since 2023
Proprietary technology to safely lengthen telomeres in human cells
Targeting biological aging at its chromosomal source
Enhancing cellular regeneration and vitality
Proprietary technology to safely lengthen telomeres in human cells
Rejuvenation is pioneering advanced technologies to rewind cellular mechanisms of aging, including therapeutic telomere extension.
Telomeres are protective DNA sequences at the ends of chromosomes that shorten with each cell division. When telomeres become critically short, cells stop dividing or die. Since cell division is essential for human life, short telomeres drive aging and disease by preventing stem cells from dividing to repair and regenerate damage from daily wear-and-tear, injury, and disease.
Short telomeres are now recognized as a fundamental cause of aging-related diseases, including pulmonary fibrosis, liver disease, and bone marrow failure.
Our breakthrough technology can safely lengthen telomeres in specific cells, potentially reversing cellular aging and preventing or treating diseases and conditions caused by short telomeres.
Short telomeres are the most common cause of familial pulmonary fibrosis and contribute to sporadic cases. Our therapy aims to restore telomere length in lung cells.
Telomere shortening in liver cells leads to cirrhosis and increased cancer risk. We’re developing treatments to maintain healthy liver cell function.
Short telomeres can cause bone marrow failure and blood disorders. Our approach could help maintain healthy blood cell production.
We use modified mRNA to temporarily activate telomerase, the enzyme that naturally extends telomeres, in specific cells.
Our proprietary lipid nanoparticle technology ensures the treatment reaches the right cells while minimizing off-target effects.
The temporary nature of our approach allows precise control over telomere extension, maintaining safety and efficacy.
Advanced telomere length analysis and biomarker tracking ensure optimal treatment outcomes.
Temporary activation avoids the cancer risks associated with permanent telomerase activation.
Our delivery system ensures the treatment reaches specific tissues and cell types.
Based on decades of research and validated through rigorous preclinical studies.
Rejuvenation’s clinical trial strategy targets unmet medical need via accelerated regulatory pathways, and broader trials to prevent or delay age-related disease in the general population.
We welcome inquiries regarding potential participation in upcoming clinical trials.
Phase I
Preclinical
Evaluating the safety and tolerability of TeloAT2 in patients with pulmonary fibrosis through telomerase activation.
Australia
24 Participants
12 Months
Phase I
Preclinical
Assessing the safety and efficacy of TeloHep in patients with chronic liver disease through telomerase activation.
Australia
32 Participants
12 Months
Phase I
Preclinical
Investigating the safety and potential efficacy of TeloHSC for hematologic conditions through telomerase activation.
Australia
12 Participants
12 Months
If you’re interested in participating in our clinical trials or would like to learn more about our ongoing research, please contact our clinical research team.
Dedicated team with decades of drug development experience from bench through FDA approval.
Stanford PhD, Co-inventor, Decade of experience with mRNA for therapeutic applications. Thesis title: Telomere extension to extend human healthspan.
Stanford PhD, Decade of experience in genetics and epigenetics of cellular reprogramming.
MBBS MRCP FRACP MD FQA, Internationally-recognized thoracic transplant physician and translational clinician researcher, Clinical Professor at U. of Queensland.
MD, PhD. Over 20 years’ experience in biomedical and translational research focusing on liver and intestinal diseases at Stanford University.
MD, 25 years of clinical development leadership including FDA approval of pirfenidone.
BA, >30 years at Stanford University
Co-inventor, Professor at Stanford University, discovered that short telomeres underlie the fatal etiology of multiple monogenic diseases.
MD, PhD, Chief of Pulmonary, Allergy and Critical Care Medicine and Professor of Medicine at Columbia University Irving Medical Center, KOL on role of short telomeres in pulmonary fibrosis.
If you’re interested in participating in our clinical trials or would like to learn more about our ongoing research, please contact our clinical research team.
Our latest research findings and scientific contributions in telomere biology and therapeutics.
Peer-reviewed publications from our research team and collaborators.
Ramunas J, Yakubov E, Brady JJ, Corbel SY, Holbrook C, Brandt M, Stein J, Santiago JG, Cooke JP, Blau HM
The FASEB Journal (2015)
We demonstrate that modified mRNA encoding TERT rapidly extends telomeres in human cells.
We’re always open to research collaborations with academic institutions and industry partners. Contact our research team to discuss potential opportunities.
Get in touch with our team to learn more about our research and potential collaborations.
Rejuvenation Technologies Inc. Mountain View, CA 94043 United States
